Analyst Jill Wu of CMB International Securities maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H (2696 – Research Report), with a price target of HK$61.98.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jill Wu’s rating is based on Shanghai Henlius Biotech’s promising pipeline of innovative drugs and its strategic global partnerships. The company has shown significant potential with HLX43, a leading PD-L1 ADC, which has demonstrated strong efficacy in clinical trials for patients with IO-resistant NSCLC, and is undergoing multiple Phase 2 trials across various indications. Additionally, HLX22, a HER2 mAb, has shown impressive results in gastric cancer trials, significantly outperforming the current standard of care, and is advancing to a Phase 3 trial.
Furthermore, serplulimab, a PD-1 inhibitor, has shown promising results in MSS colorectal cancer, indicating potential clinical benefits in a challenging treatment landscape. Henlius is also capitalizing on global biosimilar opportunities, with strong commercial performance and several products under FDA review. These factors, combined with the company’s transition to profitability and potential for significant revenue growth, support the Buy rating.